CD19 antigen density on lymphoma cells is a decisive element that influences CAR T cell therapy efficacy, with the need for more than 1000 antigens per tumor cell for CARs to be effective, while TCR-T cell therapy requires less than 100 peptides per antigen-presenting cell to be fully active [32]. Here, CD19 is linked to neoplasm.